Head-to-head · WeighScore
Aquivia Health vs Lumora
The verdict
Aquivia Health takes it — 72.2/100 to 66.1/100.
Aquivia Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the option to step up to branded Ozempic or Zepbound — an unusual side-by-side most compounded…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Aquivia Health | Lumora |
|---|---|---|
| WeighScore | 72.2/100 | 66.1/100 |
| Grade | C | C |
| Scorecard rank | #80 | #206 |
| Semaglutide | $149/mo | $199/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $179/mo | $299/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #80 · C
Strengths
- Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
- Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
- Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
- Both compounded and branded GLP-1s offered side by side — unusual for a compounded provider
- Self-pay model with no insurance required and no separate consultation fee
Where it loses points
- No public list of states served — you must complete intake to learn if your state qualifies
- No named 503A compounding pharmacy partner, limiting licensure verification
- No LegitScript, PCAB, or BBB trust badges visible
- Brand confusion: site schema names 'CatalystMD' while the customer-facing brand is Aquivia Health
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #206 · C
Strengths
- Compounded semaglutide (5 dose tiers) and tirzepatide (6 dose tiers) in injectable and sublingual forms
- Physician-founded by board-certified Drs. Sean and Shannon Arora (Arora Health & Aesthetics); clinician reviews every assessment
- LegitScript certified, HIPAA compliant, medications dispensed through licensed U.S. pharmacy partners
- Visit fees, medication, labs, and follow-up all included; full pricing shown before commitment
- Peptide therapies offered including NAD+, sermorelin, glutathione, gonadorelin, and PT-141
Where it loses points
- Pricing is fully gated behind the assessment — no public pricing; actual monthly costs unverifiable without completing intake
- Compounded medications are not FDA-approved; compounding pharmacy partners not publicly named
- Newer brand with 2026 founding; no Trustpilot rating or accessible public patient reviews found
- No dietitian, coaching, or HSA/FSA eligibility disclosed on public pages
- Claims all 50 states but 'treatment options may vary by state' with no explicit state-by-state coverage list
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.